could have been us, 10 years ago. Traventis inks preclinical deal with Takeda.
Small molecule tau drug selection/optimization phase, but not so different from Promis except that it stayed private. Another science project starting from an interesting AD hypothesis.
https://endpts.com/takeda-joins-forces-with-small-private-biotech-for-preclinical-alzheimers-research/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985489/